title: [Tracheobronchial stents: a retrospective analysis of indications, results and in particular complications].
abstract: BACKGROUND
  Tracheobronchial stents are inserted mainly in cases of malignant and benign airway stenosis. Further indications are esophago-tracheal fistulas, mediastinal fistulas and tracheomalacia.
  
  
  METHODS
  A retrospective analysis was conducted on patients' records, information provided by the general practitioners and relatives of the patients from July 1993 to December 2006 in the Department of Pneumology of the Heidehaus Hospital Hannover (since 6/05 Department of Pneumology and Internal Intensive Care Medicine, Oststadt-Heidehaus Hospital).
  
  
  RESULTS
  During the observation period of 13 years a total of 269 stents (177 permanent, 92 temporary) were implanted in 207 patients (1.3 stents per patient). The vast majority of patients (173/207) suffered from an underlying malignancy. About half of the stents were deployed in the trachea. The median length of placement was 116 days in patients with malignancies and 313 days in patients with benign diseases. In about 40 % of the patients notable complications were observed which were directly or indirectly associated with the stents. These findings show the importance of a critical indication for stent implantation. In benign diseases a stent can remain for years inside the tracheobronchial system, if it is well tolerated in the beginning. In malignant diseases the result depends decisively on the stage of the tumour: has the stent been implanted before any other tumour therapy is started or is it an end-stage tumor with no other therapeutic option? In general, complications of stents occur quite frequently.
  
  
  CONCLUSIONS
  The analysis of stent data leads to some aspects for the prevention of stent-related complications. There should be a strict indication and appropriate choice of stent material. Nevertheless, there remains an ethical dilemma in patients with end-stage disease as to whether to implant a stent or to do nothing against the tumor, because the benefit immediately after stent insertion vanishes with progression of the tumour, so causing extra complications.
authors.affiliation: Klinikum Region Hannover, Krankenhaus Oststadt-Heidehaus Hannover, Klinik für Pneumologie und internistische Intensivmedizin, Hannover. hctonn@aol.com
authors.forename: H
authors.initials: H
authors.lastname: Tonn
authors.forename: W
authors.initials: W
authors.lastname: Mall
authors.forename: K-D
authors.initials: KD
authors.lastname: Schneider
authors.forename: B
authors.initials: B
authors.lastname: Schönhofer
mesh_terms: D000402:Airway Obstruction / Q000628:therapy*; D001982:Bronchial Diseases / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015607:Stents / Q000009:adverse effects*; D014135:Tracheal Stenosis / Q000628:therapy*; D016896:Treatment Outcome